Mostrar el registro sencillo del ítem

Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies.

dc.rights.licenseopenen_US
dc.contributor.authorMARTIN DE FRÉMONT, Grégoire
dc.contributor.authorCHABROLLES, Hélène
dc.contributor.authorMIRAND, Audrey
dc.contributor.authorL'HONNEUR, Anne Sophie
dc.contributor.authorMÉLÉ, Nicolas
dc.contributor.authorDUNOGUE, Bertrand
dc.contributor.authorBOUTBOUL, David
dc.contributor.authorFARHAT, Meryem
dc.contributor.authorHACHULLA, Eric
dc.contributor.authorLAZREK, Mouna
dc.contributor.authorRIEU, Virginie
dc.contributor.authorMATHIAN, Alexis
dc.contributor.authorCHAUSSADE, Helene
dc.contributor.authorRUET, Aurelie
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBURREL, Sonia
dc.contributor.authorCOURY-LUCAS, Fabienne
dc.contributor.authorSCHUFFENECKER, Isabelle
dc.contributor.authorLEMAIGNEN, Adrien
dc.contributor.authorSTEFIC, Karl
dc.contributor.authorLE BESNERAIS, Maelle
dc.contributor.authorCARRETTE, Marion
dc.contributor.authorMOUTHON, Luc
dc.contributor.authorAVETTAND-FENOEL, Veronique
dc.contributor.authorTERRIER, Benjamin
dc.contributor.authorHADJADJ, Jérome
dc.date.accessioned2024-11-05T12:46:26Z
dc.date.available2024-11-05T12:46:26Z
dc.date.issued2024-05-20
dc.identifier.issn2056-5933en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203123
dc.description.abstractEnPatients with X linked agammaglobulinemia are susceptible to enterovirus (EV) infections. Similarly, severe EV infections have been described in patients with impaired B-cell response following treatment with anti-CD20 monoclonal antibodies (mAbs), mostly in those treated for haematological malignancies. We aimed to describe severe EV infections in patients receiving anti-CD20 mAbs for immune-mediated inflammatory diseases (IMIDs). Patients were included following a screening of data collected through the routine surveillance of EV infections coordinated by the National Reference Center and a review of the literature. Additionally, neutralising antibodies were assessed in a patient with chronic EV-A71 meningoencephalitis. Nine original and 17 previously published cases were retrieved. Meningoencephalitis (n=21/26, 81%) associated with EV-positive cerebrospinal fluid (n=20/22, 91%) was the most common manifestation. The mortality rate was high (27%). EV was the only causal agents in all reported cases. Patients received multiple anti-CD20 mAbs infusions (median 8 (5-10)), resulting in complete B-cell depletion and moderate hypogammaglobulinemia (median 4.9 g/L (4.3-6.7)), and had limited concomitant immunosuppressive treatments. Finally, in a patient with EV-A71 meningoencephalitis, a lack of B-cell response to EV was shown. EV infection should be evoked in patients with IMIDs presenting with atypical organ involvement, especially meningoencephalitis. Anti-CD20 mAbs may lead to impaired B-cell response against EV, although an underlying primary immunodeficiency should systematically be discussed.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHumans
dc.subject.enEnterovirus Infections
dc.subject.enMale
dc.subject.enFemale
dc.subject.enAntibodies
dc.subject.enMonoclonal
dc.subject.enAntigens
dc.subject.enCD20
dc.subject.enMiddle Aged
dc.subject.enAdult
dc.subject.enMeningoencephalitis
dc.subject.enAged
dc.subject.enRituximab
dc.subject.enB-Lymphocytes
dc.subject.enAgammaglobulinemia
dc.subject.enInflammation
dc.title.enSevere enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies.
dc.title.alternativeRMD Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/rmdopen-2023-004036en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed38772678en_US
bordeaux.journalRMD Open : Rheumatic & Musculoskeletal Diseasesen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue2en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD%20Open%20:%20Rheumatic%20&%20Musculoskeletal%20Diseases&rft.date=2024-05-20&rft.volume=10&rft.issue=2&rft.eissn=2056-5933&rft.issn=2056-5933&rft.au=MARTIN%20DE%20FR%C3%89MONT,%20Gr%C3%A9goire&CHABROLLES,%20H%C3%A9l%C3%A8ne&MIRAND,%20Audrey&L'HONNEUR,%20Anne%20Sophie&M%C3%89L%C3%89,%20Nicolas&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
MFP_RMDOpen_2024_Martin.pdf
Tamaño:
1.257Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem